# Lantern Pharma Inc.: financial statements, quarterly

LTRN · Nasdaq · CIK 1763950 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ltrn.md) · [Financials](/companies/ltrn/financials.md) · [Filings](/companies/ltrn/filings.md) · [Insiders](/companies/ltrn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ltrn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [2,210](/filings/0001493152-24-044010.md) | [3,573 d](/filings/0001641172-25-000926.md) | [4,251](/filings/0001641172-25-010547.md) | [3,889](/filings/0001641172-25-023471.md) | [3,717](/filings/0001493152-25-021927.md) | [4,270 d](/filings/0001493152-26-013612.md) | [3,264](/filings/0001493152-26-023740.md) | [3,068](/filings/0001493152-26-037971.md) | [2,437](/filings/0001493152-25-021927.md) | [2,745 d](/filings/0001493152-26-013612.md) | [1,725](/filings/0001493152-26-023740.md) | [1,791](/filings/0001493152-26-037971.md) |
| Operating income | $k | [(3,524)](/filings/0001493152-24-044010.md) | [(4,877) d](/filings/0001641172-25-000926.md) | [(5,732)](/filings/0001641172-25-010547.md) | [(5,408)](/filings/0001641172-25-023471.md) | [(5,180)](/filings/0001493152-25-021927.md) | [(5,896) d](/filings/0001493152-26-013612.md) | [(4,774)](/filings/0001493152-26-023740.md) | [(4,652)](/filings/0001493152-26-037971.md) | [(4,350)](/filings/0001493152-25-021927.md) | [(4,203) d](/filings/0001493152-26-013612.md) | [(3,405)](/filings/0001493152-26-023740.md) | [(3,508)](/filings/0001493152-26-037971.md) |
| Net income | $k | [(3,161)](/filings/0001493152-24-044010.md) | [(4,186) d](/filings/0001641172-25-000926.md) | [(5,441)](/filings/0001493152-25-021927.md) | [(4,960)](/filings/0001493152-25-021927.md) | [(4,506)](/filings/0001493152-25-021927.md) | [(5,875) d](/filings/0001493152-26-013612.md) | [(4,537)](/filings/0001493152-26-037971.md) | [(4,331)](/filings/0001493152-26-037971.md) | [(4,177)](/filings/0001493152-25-021927.md) | [(4,074) d](/filings/0001493152-26-013612.md) | [(3,329)](/filings/0001493152-26-037971.md) | [(7,072)](/filings/0001493152-26-037971.md) |
| Diluted EPS | $ per share | [(0.29)](/filings/0001493152-24-044010.md) | not reported | [(0.51)](/filings/0001641172-25-010547.md) | [(0.46)](/filings/0001641172-25-023471.md) | [(0.42)](/filings/0001493152-25-021927.md) | not reported | [(0.42)](/filings/0001493152-26-023740.md) | [(0.40)](/filings/0001493152-26-037971.md) | [(0.39)](/filings/0001493152-25-021927.md) | not reported | [(0.30)](/filings/0001493152-26-023740.md) | [(0.57)](/filings/0001493152-26-037971.md) |
| Basic EPS | $ per share | [(0.29)](/filings/0001493152-24-044010.md) | not reported | [(0.51)](/filings/0001641172-25-010547.md) | [(0.46)](/filings/0001641172-25-023471.md) | [(0.42)](/filings/0001493152-25-021927.md) | not reported | [(0.42)](/filings/0001493152-26-023740.md) | [(0.40)](/filings/0001493152-26-037971.md) | [(0.39)](/filings/0001493152-25-021927.md) | not reported | [(0.30)](/filings/0001493152-26-023740.md) | [(0.57)](/filings/0001493152-26-037971.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.6](/filings/0001493152-23-039896.md) | [21.9](/filings/0001641172-25-000926.md) | [18.4](/filings/0001493152-24-018422.md) | [13.0](/filings/0001493152-24-030766.md) | [8.1](/filings/0001493152-24-044010.md) | [7.5](/filings/0001493152-26-013612.md) | [6.4](/filings/0001641172-25-010547.md) | [6.1](/filings/0001641172-25-023471.md) | [8.4](/filings/0001493152-25-021927.md) | [4.4](/filings/0001493152-26-037971.md) | [4.9](/filings/0001493152-26-023740.md) | [6.7](/filings/0001493152-26-037971.md) |
| Current assets | $m | [47.4](/filings/0001493152-23-039896.md) | [43.3](/filings/0001641172-25-000926.md) | [39.5](/filings/0001493152-24-018422.md) | [35.3](/filings/0001493152-24-030766.md) | [29.9](/filings/0001493152-24-044010.md) | [25.2](/filings/0001493152-26-013612.md) | [20.8](/filings/0001641172-25-010547.md) | [17.2](/filings/0001641172-25-023471.md) | [13.5](/filings/0001493152-25-021927.md) | [10.8](/filings/0001493152-26-037971.md) | [7.1](/filings/0001493152-26-023740.md) | [8.5](/filings/0001493152-26-037971.md) |
| Total assets | $m | [47.8](/filings/0001493152-23-039896.md) | [43.6](/filings/0001641172-25-000926.md) | [39.7](/filings/0001493152-24-018422.md) | [35.6](/filings/0001493152-24-030766.md) | [30.3](/filings/0001493152-24-044010.md) | [25.6](/filings/0001493152-26-013612.md) | [21.1](/filings/0001641172-25-010547.md) | [17.4](/filings/0001641172-25-023471.md) | [13.6](/filings/0001493152-25-021927.md) | [11.0](/filings/0001493152-26-037971.md) | [7.2](/filings/0001493152-26-023740.md) | [8.6](/filings/0001493152-26-037971.md) |
| Current liabilities | $m | [2.3](/filings/0001493152-23-039896.md) | [2.7](/filings/0001641172-25-000926.md) | [4.0](/filings/0001493152-24-018422.md) | [4.6](/filings/0001493152-24-030766.md) | [3.6](/filings/0001493152-24-044010.md) | [4.3](/filings/0001493152-26-013612.md) | [4.3](/filings/0001641172-25-010547.md) | [4.9](/filings/0001641172-25-023471.md) | [4.0](/filings/0001493152-25-021927.md) | [4.5](/filings/0001493152-26-037971.md) | [3.8](/filings/0001493152-26-023740.md) | [4.3](/filings/0001493152-26-037971.md) |
| Total liabilities | $m | [2.4](/filings/0001493152-23-039896.md) | [2.7](/filings/0001641172-25-000926.md) | [4.0](/filings/0001493152-24-018422.md) | [4.7](/filings/0001493152-24-030766.md) | [3.7](/filings/0001493152-24-044010.md) | [4.4](/filings/0001493152-26-013612.md) | [4.3](/filings/0001641172-25-010547.md) | [4.9](/filings/0001641172-25-023471.md) | [4.0](/filings/0001493152-25-021927.md) | [4.5](/filings/0001493152-26-037971.md) | [3.8](/filings/0001493152-26-023740.md) | [11.8](/filings/0001493152-26-037971.md) |
| Shareholders' equity | $m | [45.4](/filings/0001493152-24-044010.md) | [40.9](/filings/0001493152-26-013612.md) | [35.8](/filings/0001493152-25-021927.md) | [30.9](/filings/0001493152-25-021927.md) | [26.6](/filings/0001493152-25-021927.md) | [21.2](/filings/0001493152-26-037971.md) | [16.8](/filings/0001493152-26-037971.md) | [12.5](/filings/0001493152-26-037971.md) | [9.6](/filings/0001493152-25-021927.md) | [6.5](/filings/0001493152-26-037971.md) | [3.4](/filings/0001493152-26-037971.md) | [(3.2)](/filings/0001493152-26-037971.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,612) d](/filings/0001493152-24-044010.md) | [(3,385) d](/filings/0001641172-25-000926.md) | [(3,069)](/filings/0001641172-25-010547.md) | [(5,191) d](/filings/0001641172-25-023471.md) | [(5,582) d](/filings/0001493152-25-021927.md) | [(3,972) d](/filings/0001493152-26-013612.md) | [(4,376)](/filings/0001493152-26-023740.md) | [(3,937) d](/filings/0001493152-26-037971.md) | [(4,572) d](/filings/0001493152-25-021927.md) | [(2,792) d](/filings/0001493152-26-013612.md) | [(3,773)](/filings/0001493152-26-023740.md) | [(2,941) d](/filings/0001493152-26-037971.md) |
| Capital expenditure | $k | [4.8 d](/filings/0001493152-24-044010.md) | [5.1 d](/filings/0001641172-25-000926.md) | [2.2](/filings/0001641172-25-010547.md) | [4.3 d](/filings/0001641172-25-023471.md) | [3.0 d](/filings/0001493152-25-021927.md) | [3.1 d](/filings/0001493152-26-013612.md) | [1.2](/filings/0001493152-26-023740.md) | [0.0 d](/filings/0001493152-26-037971.md) | [0.6 d](/filings/0001493152-25-021927.md) | [0.0 d](/filings/0001493152-26-013612.md) | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.8](/filings/0001493152-23-039896.md) | [10.9](/filings/0001493152-24-018422.md) | [10.9](/filings/0001493152-24-030766.md) | [10.9](/filings/0001493152-24-044010.md) | [10.7](/filings/0001641172-25-010547.md) | [10.8](/filings/0001641172-25-023471.md) | [10.8](/filings/0001493152-25-021927.md) | [10.8](/filings/0001493152-26-023740.md) | [10.8](/filings/0001493152-26-037971.md) | [10.8](/filings/0001493152-25-021927.md) | [11.3](/filings/0001493152-26-023740.md) | [12.4](/filings/0001493152-26-037971.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,784,146 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-037971.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.